265107-43-5

Basic information

• Product Name: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone
• Synonyms: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone;1-(6-Morpholinopyridin-3-yl)ethanone
• CAS NO: 265107-43-5
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.25
• Product Categories: pharmacetical
• Mol File: 265107-43-5.mol

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 408.302°C at 760 mmHg
• Flash Point: 200.734°C
• Appearance: /
• Density: 1.162g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: 2-8°C
• PKA: 3.40±0.10(Predicted)
• CAS DataBase Reference: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(265107-43-5)
• EPA Substance Registry System: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(265107-43-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 265107-43-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone is used as a potential inhibitor of protein kinases for its role in regulating various cellular processes. Given the involvement of protein kinases in numerous diseases, including cancer, MPYE's ability to inhibit these enzymes could lead to the development of new therapeutic agents.
Used in Drug Development:
MPYE is utilized as a promising candidate for drug development due to its chemical structure and properties. Its potential to interact with biological targets makes it a valuable compound for the creation of new medications, particularly in the realm of medicinal chemistry where its specific actions can be further explored and harnessed.
Used in Research Applications:
In the field of biological and medicinal research, 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone serves as a subject of study to understand its pharmacological activities. Further research is necessary to elucidate its full potential, including any additional applications beyond its known role as a protein kinase inhibitor.
While the specific applications of MPYE in different industries are still under investigation, its presence in the pharmaceutical and medicinal chemistry sectors highlights its potential impact on the development of future therapeutics and research initiatives.

InChI:InChI=1/C11H14N2O2/c1-9(14)10-2-3-11(12-8-10)13-4-6-15-7-5-13/h2-3,8H,4-7H2,1H3

Upstream product

• 110-91-8 morpholine 
• 55676-22-7 3-acetyl-6-chloropyridine 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 923034-23-5 dimethyl 2-(6-chloronicotinoyl)malonate 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 139042-59-4 1-(6-bromopyridin-3-yl)ethanone 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 200064-11-5 5-bromo-2-(4-morpholinyl)pyridine 

Downstream Products

• 328527-24-8 6-amino-4-cyclohexyl-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328527-11-3 2-amino-4-(3-bromophenyl)-6-[2-(4-morpholinyl)-5-pyridyl]nicotinonitrile 
• 328527-30-6 6-amino-4-(2-bromo-benzyl)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328527-32-8 6-amino-4-[1-(2-bromo-phenyl)-ethyl]-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328899-62-3 6-Amino-4-((3S,5R)-3,5-dimethyl-cyclohexyl)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 1026726-45-3 6-amino-4-(cyclohexyl-methyl-amino)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 214697-26-4 4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine 

Relevant articles and documents

Design of adenosine kinase inhibitors from the NMR-based screening of fragments

A strategy is described for designing high-affinity ligands using information derived from the NMR-based screening of fragments. The method involves the fragmentation of an existing lead molecule, identification of suitable replacements for the fragments, and incorporation of the newly identified fragments into the original scaffold. Using this technique, novel substituents were rapidly identified and incorporated into lead inhibitors of adenosine kinase that exhibited potent in vitro and in vivo activities. This approach is a valuable strategy for modifying existing leads to improve their potency, bioavailability, or toxicity profile and thus represents a useful technique for lead optimization.

NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Compound capable of effectively inhibiting or killing multi-drug resistant bacteria and preparation method and application of compound

The invention discloses a compound capable of effectively inhibiting or killing bacterial microorganisms. The compound has a structural general formula shown as the formula I (please see the formula in the description). Pharmacodynamic experiments prove that the compound can effectively inhibit or kill the broad-spectrum and multi-drug resistant staphylococcus aureus, streptococcus pneumoniae and staphylococcus aureus and is expected to be developed into a novel effective antibacterial drug with new targets.

PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES

This invention is directed to compounds of formula (I): where, n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d] pyrimidin-4-ylamine: Structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay).

Synthesis and biological evaluation of pteridine and pyrazolopyrimidine based adenosine kinase inhibitors

Three new approaches have been tested to modify existing pyridopyrimidine and alkynylpyrimidine classes of nonnucleoside adenosine kinase inhibitors 2 and 3. 4-Amino-substituted pteridines 8a-e were generally less active than corresponding 5- and 6-substituted pyridopyrimidines 2. Pyrazolopyrimidine 13c with IC50=7.5nM was superior to its open chain alkynylpyrimidine analog 13g (IC50=22nM) while pyrrolopyrimidines such as 17a were inactive.

Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor

Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) nonnucleoside AK inhibitor with oral activity in animal models of pain and inflammation.

Pyridopyrimidine analogues as novel adenosine kinase inhibitors

A novel series of pyridopyrimidine analogues 9 was identified as potent adenosine kinase inhibitors based on the SAR and computational studies. Substitution of the C7 position of the pyridopyrimidino core with C2′ substituted pyridino moiety increased the in vivo potency and enhanced oral bioavailability of these adenosine kinase inhibitors.